This webinar is looking at the published literature which has reported on differences in the performance characteristics of the two LBC preservatives SurePath and ThinPrep:
- Interfering substances and LBC performance
- Unsatisfactory rates
- Glandular disease detection
Both LBCs are in widespread use in the USA, UK, etc.
Recently, data from the national cancer screening programs of the UK, Denmark and the Netherlands have been analyzed to evaluate the impact of liquid-based cytology following replacement of the conventional Pap smear. However, there are no published randomized controlled clinical trials that directly compare SurePath and ThinPrep in a general screening setting.
These analyses are retrospective in nature and involve the evaluation of historical data that were collected following implementation of LBC in these screening programs.
[button link=”http://ascls.webedcafe.com/registration/1774/5/r/AUTO” size=”medium” color=”default”]CE ACCREDITATION[/button]
[vzaar_embed vzvd=”8815556″ ]
[accordion title=”Featured Speaker” load=”show”]
Douglas P. Malinowski, Ph.D.
BD Fellow, Global Head of Scientific Affairs, Chief Scientific Officer, BD Diagnostics – Women’s Health and Cancer
[accordion title=”Moderator” load=”hide”]
Moderator: Dillon Stickle
Editorial Assistant, ADVANCE Healthcare Network
Information collected at registration may be shared with the sponsor. For more information about our sponsor, please visit: www.BD.com